I certainly hope so. After so much self-inflicted
Post# of 148278
(Total Views: 288)
Posted On: 12/03/2019 11:15:28 AM
I certainly hope so. After so much self-inflicted damage, I don't trust management not to shoot first and ask questions later. And as much as I'd like to believe sjacob's theory that the FDA would let this one slide if the company didn't ask first (they should...), The FDA's actions haven't shown me that they "adamantly" want anything approved.
/begin rant, not directed to you Zuess/
A deal needs to get done yesterday. There's no excuse for excellent clinical data preceding selling and new lows. And I respectfully disagree with NP when he says (paraphrased) that we shouldn't accept any deal, and only the best deal will do. How much more quickly - and perhaps with more up front money? - would a deal have gotten done for HIV if we'd accepted 35% of revenue instead of 50%? Sure, that dilutes shareholders' rights to the HIV revenue stream, but selling shares at these absurd levels - with warrant coverage, no less - dilutes shareholders' rights to ALL FUTURE INCOME STREAMS. How many shares and warrants has the company sold in the last 6 months? The last year? How much have we been diluted in that time? Don't answer me please, because I actually don't want to know.
NP - Get financing settled NOW. If that's a deal, then great. Sign it. Get it done NOW. If it's another avenue for funding, get it done. I'm tired of hearing about options for funding, funding secured, deals on the table, etc. I'm tired of excuses for the share price. We're not victims of our own success, we're victims of lack of foresight and lack of funding. Don't blame Paulson investors and note holders, blame the lack of funding that created the environment for them to profit. Don't blame the OTC, get off the OTC. Don't blame the FDA, blame our failure to carefully build trial protocols to ensure we were ahead of FDA demands from the get go. Dose escalation - yes, even in P2 since the original P1 didn't include it - should have been settled long before we even got to P3. Then get the BLA done, and get it done correctly. A CLR due to carelessness would be an unacceptable outcome.
No more excuses. Nobody wants to hear them.
//end rant//
/begin rant, not directed to you Zuess/
A deal needs to get done yesterday. There's no excuse for excellent clinical data preceding selling and new lows. And I respectfully disagree with NP when he says (paraphrased) that we shouldn't accept any deal, and only the best deal will do. How much more quickly - and perhaps with more up front money? - would a deal have gotten done for HIV if we'd accepted 35% of revenue instead of 50%? Sure, that dilutes shareholders' rights to the HIV revenue stream, but selling shares at these absurd levels - with warrant coverage, no less - dilutes shareholders' rights to ALL FUTURE INCOME STREAMS. How many shares and warrants has the company sold in the last 6 months? The last year? How much have we been diluted in that time? Don't answer me please, because I actually don't want to know.
NP - Get financing settled NOW. If that's a deal, then great. Sign it. Get it done NOW. If it's another avenue for funding, get it done. I'm tired of hearing about options for funding, funding secured, deals on the table, etc. I'm tired of excuses for the share price. We're not victims of our own success, we're victims of lack of foresight and lack of funding. Don't blame Paulson investors and note holders, blame the lack of funding that created the environment for them to profit. Don't blame the OTC, get off the OTC. Don't blame the FDA, blame our failure to carefully build trial protocols to ensure we were ahead of FDA demands from the get go. Dose escalation - yes, even in P2 since the original P1 didn't include it - should have been settled long before we even got to P3. Then get the BLA done, and get it done correctly. A CLR due to carelessness would be an unacceptable outcome.
No more excuses. Nobody wants to hear them.
//end rant//
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼